COMMUNIQUÉS West-GlobeNewswire

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) Stands Out with Proprietary Next-Gen Breast CT Imaging System
22/10/2025
NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within [...]
Profusa Expands Sales Footprint with New Distributor for Lumee™ Oxygen Platform in Europe
22/10/2025
Initial target markets for commercialization include Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia Expands distributor channel coverage to ~35% of European Union population with ~300,000 [...]
24/7 Market News- Kraig Labs Scalable Spider Silk May Unlock the Future of Lightweight Body Armor and Ballistic Protection
22/10/2025
DENVER, Oct. 22, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial market news and information, believes that Kraig Biocraft Laboratories’ (OTCQB: [...]
Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET
22/10/2025
CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of [...]
Wake-Up Call: Aeroflow Sleep Survey Reveals a Growing Gap in Sleep Health Education and the Rise of DIY Sleep Trends
22/10/2025
New survey of 1,884 adults finds 81% struggle with sleep while 60% try unvetted online trends without medical consultation ASHEVILLE, N.C., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Aeroflow Sleep, a national durable medical [...]
Aeroflow Health Wins 2025 HME Provider of the Year Award
22/10/2025
Aeroflow Health's innovative approach to patient access, technology integration and partnership development sets a new standard for the home medical equipment industry ASHEVILLE, N.C. and CLEVELAND, Oct. 22, 2025 (GLOBE [...]
Elevara Medicines Raises $70 Million Series A to Advance Phase 2 Rheumatoid Arthritis Trial and Expand Pipeline
22/10/2025
Co-led b y Forbion and Sofinnova Partners, along with founding investor Monograph Capital, and Weatherden Innovative lead program, ELV001, in-licensed by Elevara from Japan’s Teijin Pharma with good tolerability and [...]
Onco3R Therapeutics reports first pre-clinical data from its best-in-class precision oncology portfolio at the 2025 AACR-NCI-EORTC symposium
22/10/2025
Three posters to be presented featuring pre-clinical data of potential best-in-class FGFR3 selective inhibitor, SMARCA2 selective inhibitor, and P53 Y220C reactivator Candidates for FGFR3 and SMARCA2 programs identified [...]
smartbax announces a €4.7 M Pre-Series A round to advance novel antibiotic compound through preclinical stage
22/10/2025
Lead antibacterial compound against a novel target in Gram-negative bacteria validated in infection models Progressing a platform of small-molecule enzymatic activators that induce self-digestion of bacteria as novel [...]
Alvotech Announces Changes in Global Business Development and Commercial Operations Team
22/10/2025
REYKJAVIK, ICELAND (OCTOBER 21, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced changes to its [...]
Alvotech Announces Changes in Global Business Development and Commercial Operations Team
22/10/2025
REYKJAVIK, Iceland, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced [...]
Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia
22/10/2025
600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated for potential [...]
Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
22/10/2025
Company previously announced it was selected as a finalist from more than 1,800 submissions Award win underscores growing impact of Aclarion’s breakthrough Nociscan solution for chronic low back pain BROOMFIELD, Colo., [...]
Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
22/10/2025
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the [...]
ENA Respiratory Attracts US$22.4m (AU$34m) to Fund Phase II Development of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
22/10/2025
MELBOURNE, Australia, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ENA Respiratory , a clinical-stage pharmaceutical company developing antiviral host defense enhancers to minimize the impact of symptomatic viral respiratory [...]
Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer
22/10/2025
Basel, October 22, 2025 - Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Novartis’ previously [...]
Ipsen annonce son intention d’acquérir ImCheck Therapeutics et étend son leadership en oncologie avec un portefeuille enrichi de produits en R&D
22/10/2025
Acquisition axée sur le programme clinique phare ICT01 dans le domaine de la leucémie myéloïde aiguë, dont les données issues de l'essai EVICTION de phase I/II en cours ont montré une réponse thérapeutique élevée. ICT01 [...]
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline
22/10/2025
Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be a new standard of [...]
Communiqué de presse : L’efdoralprine alfa de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase II sur l’emphysème par déficit en alpha-1-antitrypsine
22/10/2025
L’efdoralprine alfa de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase II sur l’emphysème par déficit en alpha-1-antitrypsine L’efdoralprine alfa a démontré sa [...]

Pages